Log in

NASDAQ:ARCTArcturus Therapeutics Stock Price, Forecast & News

$58.27
+4.17 (+7.71 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$54.39
Now: $58.27
$60.70
50-Day Range
$12.99
MA: $31.80
$58.27
52-Week Range
$5.75
Now: $58.27
$62.97
Volume503,116 shs
Average Volume1.04 million shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.19
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.
Read More
Arcturus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.79 million
Book Value$1.27 per share

Profitability

Net Income$-25,990,000.00
Net Margins-151.34%

Miscellaneous

Employees72
Market Cap$1.16 billion
Next Earnings Date8/20/2020 (Estimated)
OptionableOptionable

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

How has Arcturus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARCT stock has increased by 345.1% and is now trading at $58.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arcturus Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcturus Therapeutics.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Arcturus Therapeutics.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Ltd (NASDAQ:ARCT) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.08. The biotechnology company earned $2.65 million during the quarter, compared to analyst estimates of $7.52 million. Arcturus Therapeutics had a negative net margin of 151.34% and a negative return on equity of 409.05%. View Arcturus Therapeutics' earnings history.

What price target have analysts set for ARCT?

6 brokers have issued 12-month price targets for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $62.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $29.50 in the next year. This suggests that the stock has a possible downside of 49.4%. View analysts' price targets for Arcturus Therapeutics.

Has Arcturus Therapeutics been receiving favorable news coverage?

Media coverage about ARCT stock has trended negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutArcturus Therapeutics.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 335,000 shares, an increase of 58.3% from the April 15th total of 211,600 shares. Based on an average daily volume of 218,700 shares, the short-interest ratio is presently 1.5 days. Approximately 3.8% of the company's stock are sold short. View Arcturus Therapeutics' Current Options Chain.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Opko Health (OPK), Crispr Therapeutics (CRSP), Pfizer (PFE), Sanofi (SNY), Abbott Laboratories (ABT), Intel (INTC) and Ocular Therapeutix (OCUL).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
  • Mr. Andrew H. Sassine, CFO & Director (Age 55)
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dfpg Investments LLC (2.09%), Cormorant Asset Management LP (1.32%), Nikko Asset Management Americas Inc. (1.33%), Sumitomo Mitsui Trust Holdings Inc. (1.33%), Nikko Asset Management Americas Inc. (1.32%) and Morgan Stanley (1.02%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View institutional ownership trends for Arcturus Therapeutics.

Which major investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, DAFNA Capital Management LLC, Two Sigma Investments LP, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., and Creative Planning. View insider buying and selling activity for Arcturus Therapeutics.

Which major investors are buying Arcturus Therapeutics stock?

ARCT stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Engineers Gate Manager LP, Jane Street Group LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, Trexquant Investment LP, and BlackRock Inc.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet, and Peter C Farrell. View insider buying and selling activity for Arcturus Therapeutics.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $58.27.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $1.16 billion and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.